STORM’s METTL3 Inhibitor Effective Against AML
Plans Global Clinical RNA Epigenetic Drug Program in early 2022
Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.
You may also be interested in...
Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
Exelixis Moves Into RNA-Modifying Cancer Therapy With Storm Pact
Deal Snapshot: In addition to investigating the ADAR1 target with the UK biotech, Exelixis also has optioned a second candidate for non-Hodgkin’s lymphoma under its 2019 deal with Aurigene.
Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate
By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.